Skip to main content
  • an Accelerating Medicines Partnership® (AMP®) program
Register or Renew Workbench

NEI Main Menu

  • Register or Renew Workbench
  • About
      • About AMP PD
      • AMP PD Use Cases
      • Contact Us
      • Glossary
      • Who we are
      • Contributor Spotlights
  • News & Updates
      • News & Updates
      • Release Updates
      • AMP PD Research Plan
      • News & Articles Archive
      • Publications Archive
  • Data
      • Data
      • Harmonized Data
        • Summary Data Dashboard
        • Whole Genome Data
        • Transcriptomics Data
        • Targeted Proteomics Data
        • Clinical Assessment Data
      • Federated Data
        • GP2 Cohort Dashboard
        • Genomic Data
  • Cohorts
      • Cohorts
      • Unified Cohorts
        • BioFIND
        • HBS
        • LBD
        • LCC
        • PDBP
        • PPMI
        • STEADY-PD3
        • SURE-PD3
      • Federated Cohorts
        • GP2
  • Tools
      • Terra Platform
      • SmartConverter Data Curation
      • Visualization Tools & Resources
  • Researchers
      • Knowledge Platform Governance
      • Register for AMP PD
      • Data Use Agreement
  • Portal Resources
      • How To & References
      • AMP PD Training Videos
      • Cloud Cost Guidelines
      • Cloud Architecture
      • Computing Guidelines
  • FAQs
Register or Renew Workbench
  • Home
  • /
  • < Back To News & Updates
  • /
  • Publications Archive

Publications Archive

Replication assessment of NUS1 variants in Parkinson's disease.

November 20, 2022

Joint Modeling Study Identifies Blood-Based Transcripts Link to Cognitive Decline in Parkinson’s Disease

September 19, 2022

No association between rare TWNK variants and Parkinson’s disease in European cohorts (letter)

September 4, 2022

Evaluation of SORL1 in Lewy body dementia identifies no significant associations (letter)

August 26, 2022

Profiling the NOTCH2NLC GGC Repeat Expansion in Parkinson's Disease in the European Population (letter)

July 22, 2022

GRN mutations are associated with Lewy body dementia.

July 10, 2022

Multi-Platform Proteomic Analysis of Alzheimer’s Disease Cerebrospinal Fluid and Plasma Reveals Network Biomarkers Associated with Proteostasis and the Matrisome.

June 22, 2022

Deficiency in endocannabinoid synthase 1 DAGLB contributes to Parkinson's disease and dopaminergic neuron dysfunction.

June 17, 2022

The Parkinson’s disease protein alpha-synuclein is a direct modulator of RNA Processing-bodies and mRNA stability.

June 9, 2022

17q21.31 sub-haplotypes underlying H1-associated risk for Parkinson’s disease are associated with LRRC37A/2 expression in astrocytes.

June 1, 2022

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Next page Next
  • Last page Last
ACCELERATING MEDICINES PARTNERSHIP and AMP are registered service marks of the U.S. Department of Health and Human Services.

Footer Links

  • Contact us
  • Policy & Governance
  • Privacy Statement
  • Disclaimer
  • Site Map
  • Accessibility Policy
  • Reuse & Copyright
  • Glossary